- Home
- RPTX vs VANI Comparison
RPTX vs VANI Comparison
Compare RPTX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPTX | VANI |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4M | 91.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RPTX | VANI |
|---|---|---|
| Price | $2.56 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.5M | 178.0K |
| Earning Date | 03-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,870,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,233.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $0.91 |
| 52 Week High | $2.66 | $1.92 |
Technical Indicators
Market Signals| Indicator | RPTX | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 65.65 | 43.95 |
| Support Level | $2.52 | $1.25 |
| Resistance Level | $2.61 | $1.35 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.63 | 56.21 |
Price Performance
Historical ComparisonAbout RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.